ITeos to Participate in Upcoming Investor Conferences

GlobeNewswireNov 26 07:00 ET

Roche Anti-TIGIT Therapy Fails to Extend Survival in Late-stage Lung Cancer Trial

Seeking AlphaNov 26 06:53 ET

ITeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Simply Wall StNov 15 08:35 ET

H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $46

Moomoo NewsNov 15 06:31 ET · Ratings

Leerink Partners Maintains ITeos Therapeutics(ITOS.US) With Buy Rating

Moomoo NewsNov 14 03:33 ET · Ratings

Strategic Catalysts and Financial Stability Underpin Buy Rating for ITeos Therapeutics

TipRanksNov 13 05:48 ET · Ratings